AZD9668 + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bronchiectasis

Conditions

Bronchiectasis

Trial Timeline

Sep 1, 2008 → Apr 1, 2009

NCT ID

NCT00769119

About AZD9668 + Placebo

AZD9668 + Placebo is a phase 2 stage product being developed by AstraZeneca for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00769119. Target conditions include Bronchiectasis.

What happened to similar drugs?

1 of 10 similar drugs in Bronchiectasis were approved

Approved (1) Terminated (2) Active (8)

✅Aztreonam lysineGilead SciencesApproved

❌Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3

🔄Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3

🔄Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3

🔄AZLI + PlaceboGilead SciencesPhase 3

🔄HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01054170	Phase 2	Completed	Jan 1, 2010	Nov 1, 2010	Chronic Obstructive Pulmonary Disease (COPD)
NCT01023516	Phase 2	Completed	Nov 1, 2009	Aug 1, 2010	Chronic Obstructive Pulmonary Disease (COPD)
NCT00769119	Phase 2	Completed	Sep 1, 2008	Apr 1, 2009	Bronchiectasis
NCT00703391	Phase 2	Completed	Jun 1, 2008	Sep 1, 2008	Chronic Obstructive Pulmonary Disease (COPD)

Competing Products

20 competing products in Bronchiectasis

See all competitors

Product	Company	Stage	Hype Score
Benralizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	32
AZD5069 + Placebo	AstraZeneca	Phase 2	35
AZD0292	AstraZeneca	Phase 2	42
TIP + TIP and placebo + Placebo	Novartis	Phase 2	35
Ciprofloxacin DPI (BAYQ3939) + Placebo	Novartis	Phase 3	40
Placebo to Ciprofloxacin DPI (BAYQ3939)	Novartis	Pre-clinical	26
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo	Novartis	Phase 3	40
QBW251 + Placebo	Novartis	Phase 2	27
Ciprofloxacin (Cipro, BAYQ3939) + Placebo	Novartis	Phase 2	35
AZLI + Placebo	Gilead Sciences	Phase 3	40
Aztreonam lysine	Gilead Sciences	Approved	35
AZLI	Gilead Sciences	Phase 2	35
AZLI + Placebo	Gilead Sciences	Phase 3	40
Itepekimab (SAR440340) + Placebo	Sanofi	Phase 2	35
CSL787 + Placebo	CSL	Phase 1	29
CSL787 + Placebo	CSL	Phase 2	42
HSK31858, tablet + Placebo	Haisco Pharmaceutical Group	Phase 3	47
HSK31858 + placebo	Haisco Pharmaceutical Group	Phase 2	35
Group A + Group B	Bayer	Pre-clinical	23
BAY85-8501 + Placebo	Bayer	Phase 2	32